H107e/CAF10b
/ Statens Serum Institut
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
May 13, 2025
nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
(clinicaltrials.gov)
- P1 | N=140 | Recruiting | Sponsor: Statens Serum Institut | Trial completion date: May 2026 ➔ Nov 2026 | Trial primary completion date: May 2026 ➔ Nov 2026
Trial completion date • Trial primary completion date • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis
March 18, 2024
nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF®10b
(clinicaltrials.gov)
- P1 | N=140 | Recruiting | Sponsor: Statens Serum Institut | Not yet recruiting ➔ Recruiting
Enrollment open • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IFNG • IL17A
September 22, 2023
nTB-01: First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107/CAF®10b
(clinicaltrials.gov)
- P1b | N=140 | Not yet recruiting | Sponsor: Statens Serum Institut
New P1 trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL17A
1 to 3
Of
3
Go to page
1